Dr. Den Featured in ASCOPost: Genomic Test Identifies Patients With Prostate Cancer in Need of Intensified Salvage Therapy


Prostate cancer has been slow to catch up with breast cancer in terms of using biomarkers, but a new study represents progress in this regard. A genomic classifier called Decipher® provides important information that can be used to make treatment decisions for men with prostate cancer and a rising prostate-specific antigen (PSA) after radical prostatectomy. The genomic classifier was able to distinguish between low-risk and high-risk men in this setting who received salvage radiation therapy (with or without hormonal therapy). Results were presented at the 2015 ASTRO Annual Meeting.1

“With current standard practice, many patients are both over- and undertreated. Our study shows that you can identify high-risk men based on a genomic classifier score who should get intensified therapy, while men identified as low-risk can safely defer further treatment,” said Robert Den, MD, of the Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia.

Read more